



Our Reference: IND 20722

**ADVICE/  
INFORMATION REQUEST  
June 12, 2020**

Stanford University School of Medicine  
Attention: Kevin Schulman, MD  
Room 326, John A. and Cynthia Fry Gunn Building  
366 Galvez Street  
Stanford, CA 94305

Dear Dr. Schulman:

Please refer to your Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act for “Anti-SARS-CoV-2 Convalescent Plasma” for the protocol titled, “Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO).”

Please also refer to your amendment submitted to your IND on June 10, 2020 and received June 11, 2020. Your study may proceed.

If you have any question, please contact Ms. Cherry Geronimo, RPMS Team Lead, at [cherry.geronimo@fda.hhs.gov](mailto:cherry.geronimo@fda.hhs.gov).

Sincerely,

**Orieji Illoh -S**

Digitally signed by Orieji Illoh -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=Orieji Illoh -S,  
0.9.2342.19200300.100.1.1=2000420941  
Date: 2020.06.12 18:10:19 -04'00'

Orieji Illoh, MD  
Director  
Division of Blood Components and Devices  
Office of Blood Research and Review  
Center for Biologics Evaluation and Research